# AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

> **NCT00325715** · PHASE1 · COMPLETED · sponsor: **Allergan** · enrollment: 150 (actual)

## Conditions studied

- Peptic Ulcer

## Interventions

- **DRUG:** AGN 201904
- **DRUG:** esomeprazole

## Key facts

- **NCT ID:** NCT00325715
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2011-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00325715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00325715, "AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00325715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*